Financial Data and Key Metrics Changes - Total revenue for 2025 grew 29% to $96 million, landing at the high end of guidance, which was raised twice in the second half of the year [6][14] - Adjusted EBITDA increased to $25 million or 26% of revenue, up from $13 million or 18% in 2024 [6][18] - Adjusted net income for Q4 was $1.9 million, compared to an adjusted net loss of $0.1 million in Q4 of the prior year [17] Business Line Data and Key Metrics Changes - In Q4, total revenue reached $24.8 million, increasing 20% year-over-year, primarily driven by the biopreservation media (BPM) franchise [7][14] - BPM product line accounted for approximately 85% of total revenue, with commercial BPM customers accounting for nearly 50% of revenue, up from the low 40s range in 2024 [7][8] - Full year growth across all product lines except hPL media, which was flat year-over-year due to import restrictions in China [15] Market Data and Key Metrics Changes - BioLife's BPM products are embedded in 16 approved therapies and utilized in over 250 commercially sponsored CGT trials in the U.S., representing over 70% market share [8] - Anticipation of up to 5 unique therapy approvals over the next 12 months, along with 1 new indication and at least 1 geographic expansion [9] Company Strategy and Development Direction - The company aims to drive sustainable, profitable growth and shareholder value with a streamlined portfolio centered on market-leading consumables [5] - Focus on expanding role within clinical and commercial programs beyond biopreservation media, with cross-sell opportunities expected to increase revenue per patient dose by 2 to 3 times [9][10] - Strategic distribution and product development agreement with Qkine Limited to expand product offerings in cytokines [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the cell and gene therapy (CGT) market, supported by encouraging clinical data and strategic investments by large pharma [12] - Guidance for 2026 includes revenue between $112 million and $115 million, reflecting growth of 17%-20% [11][20] - Expectation of full year positive GAAP net income for the first time in many years, along with further expansion of adjusted EBITDA margins [21] Other Important Information - Cash and marketable securities balance at December 31, 2025, was $120.2 million, up from $105.4 million at December 31, 2024 [19] - The company implemented ERP manufacturing modules to enhance operational efficiency [14] Q&A Session Summary Question: Guidance assumptions between commercial and clinical - Management expects commercial customers to represent 50%-55% of total revenue in 2026, with no significant uptick in clinical customer orders observed [25] Question: Bag yield impact on margins - Management indicated a 2 to 3-point headwind on gross margin in the second half of 2025 due to bag yield issues, with improvements expected by Q4 2026 [27] Question: Exposure to CAR T market - Over 80% of commercial exposure is related to CAR T therapies, with patient access being a key constraint to growth [33] Question: Cross-selling initiative success - Growth from non-BPM tools is expected to outpace BPM growth, with metrics on customer usage of multiple products being a future goal [40] Question: Partnership with Qkine - The partnership is seen as a long-term strategic move, with revenue expected to materialize in 2026 [46] Question: Potential acquisitions in biopreservation - Management is monitoring potential acquisitions but has not identified any that provide a competitive advantage beyond what is already offered [61]

Financial Performance - In 2025, total revenue grew 29% to $96 million, reaching the high end of guidance, with Q4 revenue at $24.8 million, a 20% year-over-year increase [6][15][16] - Adjusted EBITDA for Q4 was $6.9 million, or 28% of revenue, compared to $3.7 million or 18% in Q4 2024; full year adjusted EBITDA was $25 million or 26% of revenue, up from $13.3 million or 18% in the prior year [19][18] - Adjusted net income for Q4 was $1.9 million, compared to an adjusted net loss of $0.1 million in Q4 2024; full year adjusted net income was $6.3 million, compared to an adjusted net loss of $2.9 million in the prior year [18][19] Business Line Performance - The biopreservation media (BPM) product line accounted for approximately 85% of total revenue, with commercial BPM customers contributing nearly 50% of revenue, up from the low 40s range in 2024 [8][6] - Growth was observed across all product lines except for hPL media, which remained flat due to import restrictions in China [16] Market Dynamics - BioLife's BPM products are embedded in 16 approved therapies and utilized in over 250 commercially sponsored CGT trials in the U.S., representing over 70% market share [9] - The company anticipates up to five unique therapy approvals and one geographic expansion in the next 12 months, indicating a positive regulatory environment [10] Strategic Direction - The company aims to expand its role in clinical and commercial programs beyond biopreservation media, with a focus on cross-selling additional cell processing tools [10][11] - A strategic distribution agreement with Qkine Limited was established to enhance the product offering in cytokines, complementing the emerging hPL product line [12] Management Commentary - Management expressed confidence in the long-term trajectory of the cell and gene therapy (CGT) market, citing favorable macro conditions and increased strategic investments by large pharma [13] - The company expects to achieve full year positive GAAP net income for the first time in many years and further expansion of adjusted EBITDA margins in 2026 [22] Other Important Information - The company implemented ERP manufacturing modules to enhance operational efficiency without disrupting operations [15] - Cash and marketable securities balance at year-end 2025 was $120.2 million, up from $105.4 million at year-end 2024 [20] Q&A Session Summary Question: Can you provide more color on the assumptions between commercial and clinical growth? - Management expects commercial customers to represent 50%-55% of total revenue in 2026, with no significant uptick in clinical customer orders observed yet [25][26] Question: What was the impact of bag yield on margins in the second half of 2025? - Management indicated a 2-3 point headwind on gross margin due to bag yield issues, with solutions expected to be implemented by Q4 2026 [27][28] Question: What is the company's exposure to the CAR-T market? - Over 80% of commercial exposure is related to CAR-T therapies, with patient access being a key constraint to growth [34] Question: Can you elaborate on the cross-selling initiative? - The growth rate of non-BPM tools is expected to outpace BPM tools, with a focus on tracking customer usage of multiple products [41][42] Question: What is the margin profile for the new partnership with Qkine? - Specific margins were not disclosed, but the partnership is viewed as a long-term strategic move rather than a short-term revenue generator [46][48] Question: Are there plans for further acquisitions in biopreservation? - Management is monitoring potential acquisitions but has not identified any that would provide a competitive advantage beyond the recent PanTHERA acquisition [62]

Financial Data and Key Metrics Changes - In Q2 2025, total revenue increased by 29% year over year to $25.4 million, driven by a 28% increase in cell processing revenue [16][6] - Adjusted EBITDA margin expanded by 400 basis points to 24%, reflecting strong operating leverage [6] - GAAP net loss was $15.8 million or $0.33 per share, compared to a net loss of $5.6 million or $0.12 per share in the prior year [20][16] Business Line Data and Key Metrics Changes - Cell processing revenue reached $23 million, marking a 28% year-over-year increase and a 6% sequential increase [8] - Biopreservation media (BPM) products accounted for approximately 85% of Q2 cell processing revenue, with top 20 customers contributing about 80% of BPM revenue [8][9] - Adjusted operating expenses totaled $16.9 million, up from $14 million in the prior year, largely due to increased stock-based compensation and IPR&D expenses related to the Panthera acquisition [19][16] Market Data and Key Metrics Changes - At the end of Q2, BPM products were embedded in 16 approved therapies and used in over 250 relevant commercially sponsored CGT trials in the U.S., representing over a 70% market share [10] - The company maintains a strong position in late-stage clinical development, with nearly 80% market share in Phase 3 clinical trials [10] Company Strategy and Development Direction - The company is focused on operational execution and disciplined capital allocation, with a sharpened focus on its product portfolio and market share in cell processing [7] - A strategic investment in Pluristics was made to explore product portfolio expansion into relevant adjacencies [12] - The company raised its full-year revenue guidance to $100 million to $103 million, reflecting a growth of 22% to 25% [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macro uncertainties, citing strong visibility from major customers [26] - The FDA's recent decision to remove the REMS requirement is viewed as a positive development for the CGT landscape, potentially enhancing patient access to therapies [13] - The company expects continued strength in cell processing revenue despite broader market uncertainties [7] Other Important Information - The company reported cash and marketable securities of $100.2 million at the end of Q2 2025 [21] - The acquisition of Panthera is expected to enhance market leadership in biopreservation and introduce new product lines [54] Q&A Session Summary Question: Guidance visibility and commercial ramps - Management indicated good visibility into revenue from top customers and expressed confidence in the second half of the year despite potential lumpiness between Q3 and Q4 [26][27] Question: Cross-selling dynamics - Management noted early traction in cross-selling efforts, with larger accounts showing interest in additional products [31] Question: CryoCase timeline - Management is in discussions with a large customer regarding changes to the CryoCase and has over 30 customers evaluating it [35] Question: Pluristics investment and competition - Management does not view Pluristics as a competitive threat but is interested in their assay development capabilities [40] Question: Panthera updates - The company remains on track to have commercial products from Panthera in the market by the second half of next year [42] Question: Demand trends in early clinical stages - Management noted a slight softness in demand from smaller Phase I and II customers but expects overall growth to continue [49] Question: Distribution channel visibility - Management has not seen any weakness in the distribution channel and remains confident in its strength for the remainder of the year [53] Question: M&A strategy - The company emphasizes a disciplined approach to M&A, focusing on strategic rationale and market leadership [60]

Financial Data and Key Metrics Changes - The company reported Q1 revenue of $23.9 million, representing a 30% year-over-year increase, primarily driven by a 33% increase in the cell processing platform revenue [14][17] - GAAP gross margin for Q1 2025 was 63%, consistent with Q1 2024, while adjusted gross margin remained at 66% [14][15] - Adjusted EBITDA for Q1 2025 was $5.7 million, or 24% of revenue, compared to $2.6 million, or 14% of revenue in the prior year [17][18] Business Line Data and Key Metrics Changes - Cell processing revenue increased to $21.6 million, a 33% year-over-year increase and a 6% sequential increase from Q4 last year [6][7] - The biopreservation media (BPM) product line continues to be a significant driver, with 80% of BPM revenue coming from the top 20 customers [8][9] - Approximately 60% of BPM revenue comes from direct sales, with 40% from distribution channels [9] Market Data and Key Metrics Changes - The company estimates that its BPM products are used in at least 70% of relevant commercially sponsored cell and gene therapy (CGT) trials in the U.S., with a share of late-stage clinical trials exceeding 75% [10] - The company has a strong position in the market, with only homebrew formulations as meaningful alternatives to its offerings [11] Company Strategy and Development Direction - The company is focused on delivering leading solutions to the cell and gene therapy market and is committed to sustainable growth throughout 2025 [7][13] - The acquisition of Panthera CryoSolutions is aimed at expanding the biopreservation portfolio and enhancing scientific capabilities [13] - The company is optimistic about long-term industry fundamentals but acknowledges near-term uncertainties from factors like tariffs and NIH funding cuts [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating potential headwinds with minimal impact on financial results [71] - The company reaffirmed its full-year revenue guidance of $95.5 million to $99 million, with growth led by the cell processing platform [14][19] Other Important Information - The company ended the quarter with over $100 million in cash, providing a solid foundation for growth initiatives [7] - Adjusted operating income for Q1 2025 was $900,000, compared to an adjusted operating loss of $2.4 million in Q1 2024 [17] Q&A Session Summary Question: Insights on clinical side demand trends - Management noted that clinical customers showed reasonable performance, with growth driven primarily by commercial customers [22][23] Question: Details on the Panthera acquisition - The acquisition was timed to leverage proven technology and aims to develop next-generation cryopreservation products [26][27] Question: Current status of pricing changes - Management indicated that they are more than halfway through pricing adjustments for key customers, with a gradual implementation over three years [33][34] Question: Impact of tariffs and NIH funding - Management assessed that they have limited exposure to tariffs and NIH funding cuts, with minimal impact expected on their cost of goods [39][40] Question: Future M&A pipeline and CapEx projects - The company is exploring small tuck-in acquisitions and has plans for significant CapEx projects, including facility expansions [46][47] Question: Potential for media swaps with Panthera products - Management indicated that switching costs for customers to change biopreservation media are significant, making it unlikely for existing commercial products to switch [52][54] Question: Ability to pass on tariff costs to customers - Management confirmed that they could implement surcharges for any material increases in costs due to tariffs [55][56]

Financial Data and Key Metrics Changes - The company reported Q1 revenue of $23.9 million, representing a 30% year-over-year increase, primarily driven by a 33% increase in the cell processing platform revenue [13][15] - GAAP gross margin for Q1 2025 was 63%, consistent with Q1 2024, while adjusted gross margin remained at 66% [13][14] - Adjusted EBITDA for Q1 2025 was $5.7 million, or 24% of revenue, compared to $2.6 million, or 14% of revenue in the prior year [15][16] Business Line Data and Key Metrics Changes - Cell processing revenue increased to $21.6 million, a 33% year-over-year increase and a 6% sequential increase from Q4 last year [6][15] - The biopreservation media (BPM) product line continues to be the primary driver of revenue, with top 20 customers accounting for approximately 80% of BPM revenue [6][7] - The company expects continued growth from commercial customers, with around 40% of BPM revenue coming from customers with approved commercial therapies [7][12] Market Data and Key Metrics Changes - Approximately 60% of BPM revenue comes from direct sales, while 40% is through distribution [7] - The company estimates its BPM products are used in at least 70% of relevant commercially sponsored cell and gene therapy trials in the U.S., with a share of late-stage clinical trials exceeding 75% [8][9] Company Strategy and Development Direction - The company is committed to delivering leading solutions to the cell and gene therapy market and has reaffirmed its full-year revenue guidance of $95.5 million to $99 million [12][13] - The acquisition of Panthera CryoSolutions is aimed at expanding the biopreservation portfolio and enhancing scientific capabilities, with a focus on developing next-generation cryopreservation products [12][26] - The company is actively monitoring potential near-term headwinds from tariffs and NIH funding cuts but does not expect any material impact on its financial outlook [12][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating potential headwinds with minimal impact on financial results, emphasizing the strength of the balance sheet with over $100 million in cash [6][68] - The company remains optimistic about long-term industry fundamentals despite recognizing near-term uncertainties [12][68] Other Important Information - The company expects adjusted gross margin for the full year to be in the mid-60s, with a reduction in GAAP net loss and expansion in adjusted EBITDA margin due to higher expected revenue [18] - The company has a cash and marketable securities balance of $107.6 million as of March 31, 2025 [16] Q&A Session Summary Question: Insights on clinical side demand trends - Management noted that clinical customers buying directly showed reasonable performance, with growth driven primarily by commercial customers [21][22] Question: Rationale behind Panthera acquisition - The acquisition was timed to leverage proven technology and enhance the development of next-generation cryopreservation products [24][26] Question: Current status of pricing changes - Management indicated that they are more than halfway through pricing adjustments for key customers, with a gradual implementation over three years [31][32] Question: Impact of tariffs and NIH funding - Management assessed that they have limited exposure to tariffs and NIH funding cuts, with most products manufactured in the U.S. [37][39] Question: Future M&A pipeline - The company is exploring small tuck-in acquisitions similar to Panthera, with a strict filter criteria for potential targets [32][33] Question: Incremental OpEx from Panthera acquisition - Expected incremental OpEx from the Panthera acquisition is around $1 million for the remaining nine months of the year [60]